Trial Profile
An Open-label Study to Investigate the Tolerability, Pharmacokinetics and Anti-tumour Effect Following Photodynamic Therapy (PDT) With Single-ascending Doses of LUZ11 in Patients With Advanced Head and Neck Cancer
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 28 Mar 2024
Price :
$35
*
At a glance
- Drugs Redaporfin (Primary)
- Indications Head and neck cancer
- Focus Adverse reactions; First in man
- Sponsors Luzitin
- 28 Mar 2024 Status changed from recruiting to completed.
- 02 Jun 2017 Results (n=13) form phase I portion of the study, presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
- 01 Mar 2016 Planned End Date changed from 1 Dec 2014 to 1 Jul 2016, according to ClinicalTrials.gov record.